Several months after the FDA’s controversial decision to approve aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s disease, payors are still determining how they will cover the drug, while hospitals and health systems grapple with decisions about which patients, if any, should be offered the amyloid plaque–targeting agent.
Meanwhile, two congressional committees—the House Committee on Oversight and Reform and the Committee on Energy and